---
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/100000000439065.md"
description: "Fate Therapeutics remains a high-risk, high-reward biotech play, with recent developments mainly centred around its cell therapy pipeline, particularly FT819 (off-the-shelf CAR-T) for autoimmune diseases."
datetime: "2026-02-01T14:37:58.000Z"
locales:
  - [en](https://longbridge.com/en/topics/100000000439065.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/100000000439065.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/100000000439065.md)
author: "[mkjh](https://longbridge.com/en/profiles/25461045.md)"
generator: "portal-rs"
---

# Fate Therapeutics remains a high-risk, high-reward…


### Related Stocks

- [FATE.US](https://longbridge.com/en/quote/FATE.US.md)

## Comments (1)

- **Dolphin fans · 2026-02-02T08:23:59.000Z**: Worth watching closely


---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**